Adrenal schwannoma is a rare adrenal incidentaloma. It is a benign tumor arising from the Schwann cells. Differentiating benign from malignant adrenal lesions requires a combination of clinical, biochemical, imaging, and histopathological findings. 68Ga-DOTANOC PET/CT is one of the sensitive imaging modalities to detect adrenal lesions such as pheochromocytoma. Multiple benign and malignant lesions show somatostatin receptor expression causing a high probability of false-positive findings on somatostatin receptor imaging. We present a case of adrenal incidentaloma positive on 68Ga-DOTANOC PET, which revealed a benign adrenal spindle cell tumor on histopathology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000004444 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congenital hyperinsulinism in the Ukraine: a 10-year national study.
Front Endocrinol (Lausanne)
January 2025
Department of Clinical and Biomedical Science, University of Exeter Medical School, Exeter, United Kingdom.
Introduction: Congenital Hyperinsulinism (CHI) has not been previously studied in Ukraine. We therefore aimed to elucidate the genetics, clinical phenotype, histological subtype, treatment and long-term outcomes of Ukrainian patients with CHI.
Methods: Forty-one patients with CHI were recruited to the Ukrainian national registry between the years 2014-2023.
Comparison of Ga-DOTANOC and F-FDOPA PET/CT for Detection of Recurrent or Metastatic Paragangliomas.
Radiol Imaging Cancer
January 2025
From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, 200032 Shanghai, China; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
Purpose To evaluate the diagnostic performance of gallium 68 (Ga)-DOTA-NaI3-octreotide (Ga-DOTANOC) and fluorine 18 (F)-fluoro-l-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in detecting recurrent or metastatic paragangliomas. Materials and Methods This single-center retrospective study included patients with paragangliomas who underwent both Ga-DOTANOC PET/CT and F-FDOPA PET/CT between August 2021 and December 2023. The diagnostic performance of these two tracers in detecting recurrent or metastatic tumors was compared using several metrics, including sensitivity, negative predictive value, and accuracy.
View Article and Find Full Text PDFDiagnostic performance of [18 F]FDOPA PET/CT and other tracers in pheochromocytoma: A meta-analysis.
Acad Radiol
September 2024
First Hospital of Shanxi Medical University, Clinical Research Center For Metabolic Diseases Of Shanxi Medical University, Taiyuan, Shanxi 030000, China (Y.R., J.Y.). Electronic address:
Article Synopsis
- The study evaluates the effectiveness of various PET-CT tracers in diagnosing pheochromocytoma (PHEO), a type of tumor, by analyzing data from multiple medical research databases.
- It includes a meta-analysis of 16 studies, finding that [18 F]FDOPA PET/CT has the highest sensitivity (97%) and specificity (94%) for PHEO detection, with an impressive diagnostic accuracy of 98.9%.
- The research concludes that while PET/CT is generally effective for PHEO diagnosis, [18 F]FDOPA is the standout tracer among those evaluated, suggesting a need for further studies on other tracers.
An Unusual Occurrence of Metastases to Multiple Muscles in Neuroblastoma.
Indian J Nucl Med
August 2024
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Neuroblastoma presenting with multiple muscles and subcutaneous tissue metastases is rarely reported in the literature. We would like to highlight such infrequent occurrences for increasing the clinical acumen of the medical fraternity with an aim to deliver proper therapy to patients.
View Article and Find Full Text PDFProlactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report.
Neurol India
July 2024
Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Pituitary carcinoma is a rare entity comprising 0.1-0.2% of all pituitary tumors and presents significant diagnostic and therapeutic challenges.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!